# Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants

> **NCT05599802** · PHASE1 · UNKNOWN · sponsor: **AIM Vaccine Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 variant mRNA vaccine low dose
- **BIOLOGICAL:** SARS-CoV-2 variant mRNA vaccine high dose

## Key facts

- **NCT ID:** NCT05599802
- **Lead sponsor:** AIM Vaccine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02
- **Primary completion:** 2023-05
- **Final completion:** 2024-05
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2022-11-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599802, "Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05599802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*